In the glittering world of celebrity-endorsed weight loss transformations and viral before-and-after photos, a darker narrative is emerging from the shadows ...

New research suggests that Ozempic and similar weight loss medications have the potential to be as big a game changer in addiction treatment as they have been in reducing obesity.

Investors are upset at a lack of clarity over the results of Wegovy successor CagriSema after trials published in December.

The drugmaker behind the medical phenomenon semaglutide ... the lower-than-expected average weight loss. But it’s the hushed nature of the flexible protocol that has concerned investors.

Novo Nordisk (NVO) stock in focus as company announces new Phase 3 trial for its next-gen weight loss drug CagriSema despite disappointing early results. Read more here.

President Donald Trump and HHS Secretary Robert F. Kennedy Jr. said they will be studying the "threat" to children posed by antidepressants and obesity medications.

With its Q4 2024 results on Wednesday, Novo Nordisk (NVO) announced a new Phase 3 trial to test its highly-anticipated weight loss therapy ... GLP-1 receptor agonist semaglutide, is considered ...

LONDON/SAN FRANCISCO (Reuters) - Novo Nordisk is under pressure from investors for more information about its next-generation obesity drug candidate CagriSema amid a lack of clarity over trial results ...

In the STEP trial, which studied semaglutide for weight loss, 89.6% of patients completing ... She has, however, kept to the recommended dosing protocol in the hope of losing more weight.

Investors and analysts reacted immediately to Novo's revelation. The price of Novo's common stock declined dramatically. From ...